<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04042441</url>
  </required_header>
  <id_info>
    <org_study_id>NN5401-4525</org_study_id>
    <secondary_id>U1111-1227-8654</secondary_id>
    <nct_id>NCT04042441</nct_id>
  </id_info>
  <brief_title>A Research Study, Looking at How Ryzodeg® (Insulin Degludec/Insulin Aspart) Works in People With Type 2 Diabetes in Local Clinical Practice</brief_title>
  <acronym>ARISE</acronym>
  <official_title>A Multi-centre Prospective Non-interventional Study Investigating the Clinical Effectiveness of Ryzodeg® (Insulin Degludec/Insulin Aspart) in Patients With Type 2 Diabetes Mellitus in a Real-world Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to collect information on how Ryzodeg® works in real world
      patients and to see if Ryzodeg® can lower blood sugar levels. Participants will get Ryzodeg®
      as prescribed to them by their doctor. The study will last for about 6 to 9 months.
      Participants will be asked questions about their health and their diabetes treatment as part
      of their normal doctor's appointment.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 29, 2019</start_date>
  <completion_date type="Anticipated">November 12, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 12, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in local laboratory measured glycosylated haemoglobin (HbA1c)</measure>
    <time_frame>From baseline (week 0) to end of study (week 26-36)</time_frame>
    <description>Percentage point</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c less than 7% (Yes/No)</measure>
    <time_frame>At the end of study (week 26-36)</time_frame>
    <description>Percentage of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c less than pre-defined individual treatment target (Yes/No)</measure>
    <time_frame>At the end of study (week 26-36)</time_frame>
    <description>Percentage of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in local laboratory measured fasting plasma glucose (FPG)</measure>
    <time_frame>From baseline (week 0) to end of study (week 26-36)</time_frame>
    <description>mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in local laboratory measured FPG</measure>
    <time_frame>From baseline (week 0) to end of study (week 26-36)</time_frame>
    <description>mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin dose (total, basal, prandial)</measure>
    <time_frame>From baseline (week 0) to end of study (week 26-36)</time_frame>
    <description>units/day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>From baseline (week 0) to end of study (week 26-36)</time_frame>
    <description>Kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patient recollection of non-severe hypoglycaemic episodes</measure>
    <time_frame>At baseline (week 0). Episodes occurring within 4 weeks prior to initiation of treatment with Ryzodeg®</time_frame>
    <description>Number of episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patient recollection of non-severe hypoglycaemic episodes</measure>
    <time_frame>At the end of study (week 26-36). Episodes occurring within 4 weeks prior to end of study</time_frame>
    <description>Number of episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patient recollection of nocturnal non-severe hypoglycaemic episodes</measure>
    <time_frame>At baseline (week 0). Episodes occurring within 4 weeks prior to initiation of treatment with Ryzodeg®</time_frame>
    <description>Number of episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patient recollection of nocturnal non-severe hypoglycaemic episodes</measure>
    <time_frame>At end of study (week 26-36). Episodes occurring within 4 weeks prior to end of study</time_frame>
    <description>Number of episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patient recollection of overall severe hypoglycaemic episodes</measure>
    <time_frame>At baseline (week 0). Episodes occurring within 26 weeks prior to initiation of treatment with Ryzodeg®</time_frame>
    <description>Number of episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patient recollection of overall severe hypoglycaemic episodes</measure>
    <time_frame>At the end of study (week 26-36). Episodes occurring within 26 weeks prior to end of study</time_frame>
    <description>Number of episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of weekly self-measured plasma glucose (SMPG) measurements</measure>
    <time_frame>At baseline (week 0). Measurements occurring within 7 days prior to initiation of treatment with Ryzodeg®</time_frame>
    <description>Number of measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of weekly self-measured plasma glucose (SMPG) measurements</measure>
    <time_frame>At end of study (week 26-36). Measurements occurring within 7 days prior to end of study</time_frame>
    <description>Number of measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reason for initiating Ryzodeg® (pre-specified response option(s))</measure>
    <time_frame>At baseline (week 0)</time_frame>
    <description>Percentage of patients per response option</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinue treatment with Ryzodeg® during the treatment period (Yes/No)</measure>
    <time_frame>At treatment discontinuation (week 0-36) or at end of study (week 26-36). After initiation of treatment with Ryzodeg® until treatment discontinuation</time_frame>
    <description>Percentage of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reason for discontinuing treatment with Ryzodeg® during the treatment period, if applicable, (pre-specified response option(s))</measure>
    <time_frame>At treatment discontinuation (week 0-36). After initiation of treatment with Ryzodeg® until treatment discontinuation</time_frame>
    <description>Percentage of patients per response option</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time period from initiation to discontinuation of treatment with Ryzodeg®</measure>
    <time_frame>At treatment discontinuation (week 0-36). After initiation of treatment with Ryzodeg® until treatment discontinuation</time_frame>
    <description>Days</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1112</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Ryzodeg® as per local practice</arm_group_label>
    <description>Real-world population of patients with Diabetes Mellitus, Type 2 (T2DM), who have been initiated or switched to Ryzodeg® from previous antihyperglycaemic treatment according to local clinical practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Degludec/Insulin Aspart</intervention_name>
    <description>Insulin Degludec/Insulin Aspart (Ryzodeg®) as prescribed by the patient's treating physician. The decision to initiate or switch into treatment with commercially available Ryzodeg® has been made before, and independently from, the decision to include the patient in this study.</description>
    <arm_group_label>Ryzodeg® as per local practice</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Real-world population of type 2 patients, who have been initiated or switched to Ryzodeg®
        from previous antihyperglycaemic treatment according to local clinical practice.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent obtained before any study-related activities. Study-related
             activities are any procedures related to recording of data according to the protocol.

          -  The decision to initiate or switch into treatment with commercially available Ryzodeg®
             has been made by the patient/Legally Acceptable Representative (LAR) and the treating
             physician based on local label before, and independently from, the decision to include
             the patient in this study.

          -  Male or female, age above or equal to 18 years at the time of signing informed
             consent.

          -  Diagnosed with T2DM and treated with any anti-hyperglycaemic medication(s) other than
             Ryzodeg® for at least 26 weeks prior to signing informed consent.

          -  Available and documented HbA1c value for 12 weeks or less prior to signing informed
             consent.

        Exclusion Criteria:

          -  Hypersensitivity to the active substance or to any of the excipients as specified in
             the Ryzodeg® local label.

          -  Previous participation in this study. Participation is defined as signed informed
             consent.

          -  Mental incapacity, unwillingness or language barriers precluding adequate
             understanding or cooperation.

          -  Previous treatment with Ryzodeg®.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Reporting Anchor and Disclosure (1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <zip>2500</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Elizabeth Vale</city>
        <state>South Australia</state>
        <zip>5112</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Keswick</city>
        <state>South Australia</state>
        <zip>5035</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Cooloongup</city>
        <state>Western Australia</state>
        <zip>6168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Guwahati</city>
        <state>Assam</state>
        <zip>781033</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560024</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560043</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440015</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Delhi</city>
        <state>New Delhi</state>
        <zip>110088</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bhubaneswar</city>
        <state>Orissa</state>
        <zip>751030</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mohali</city>
        <state>Punjab</state>
        <zip>160062</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600040</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Howrah</city>
        <state>West Bengal</state>
        <zip>711103</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>New Delhi</city>
        <zip>110088</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kedah</city>
        <zip>08000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kelantan</city>
        <zip>15200</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kota Bharu, Kelantan</city>
        <zip>16150</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50450</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kuching</city>
        <zip>93350</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Melaka</city>
        <zip>75000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Melaka</city>
        <zip>75450</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Penang</city>
        <zip>10450</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Perak</city>
        <zip>35800</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Perlis</city>
        <zip>01000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Putrajaya</city>
        <zip>62250</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Selangor</city>
        <zip>47500</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Selangor</city>
        <zip>47810</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Aklan</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Cebu City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Davao City</city>
        <zip>8000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Iloilo</city>
        <zip>5000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Makati City</city>
        <zip>1229</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Manila</city>
        <zip>1015</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1102</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Jeddah</city>
        <zip>22252</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Jeddah</city>
        <zip>23216</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Jeddah</city>
        <zip>23521</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Jeddah</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Makkah</city>
        <zip>24381</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Riyadh</city>
        <zip>12311</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Riyadh</city>
        <zip>14214</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Riyadh</city>
        <zip>14611</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Riyadh</city>
        <zip>14963</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Port Elizabeth</city>
        <state>Eastern Cape</state>
        <zip>6045</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Port Elizabeth</city>
        <state>Eastern Cape</state>
        <zip>6201</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>1827</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Lenasia</city>
        <state>Gauteng</state>
        <zip>1827</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0181</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Berea</city>
        <state>KwaZulu-Natal</state>
        <zip>4091</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Alberton</city>
        <zip>1449</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>India</country>
    <country>Malaysia</country>
    <country>Philippines</country>
    <country>Saudi Arabia</country>
    <country>South Africa</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 31, 2019</study_first_submitted>
  <study_first_submitted_qc>August 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2019</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
    <ipd_url>http://novonordisk-trials.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

